ALEMBIC PHARMA Q1 FY 21 RESULTS REVIEW
Alembic Pharmaceuticals
Limited reported its consolidated financial
results for the quarter ending 301h June 2020.
Financial Highlights for
Q1 FY21
• Net Sales up 41 % to Rs 1341 crores
• Profit before tax up 131 % to Rs 368 crores
• Net Profit up 144% to Rs 301 crores
Mr. Pranav Amin, Managing
Director, Alembic Pharmaceuticals Limited said-
"It was an excellent quarter for the company backed by growth
in all the international markets.
Despite exceptionally, challenging
circumstances, the operating
teams ensured profitability and growth."
Operational Highlights
International Business
• International formulations grew 70% to Rs
771 crores in the quarter.
• US Generics grew 73% to Rs 596 crores in the
quarter.
• Ex-US International
Formulations grew 62% to Rs 175 crores in the quarter.
• 6 ANDA approvals received during the
quarter, Cumulative ANDA approvals at
125 (including 14 tentative).
• 8 ANDA filings during the quarter; Cumulative ANDA filings at 191.
India Formulations Business
• India formulations business for the quarter
de-grew by 6% to Rs 306 crores
Summary of Total Revenue is as under (Rs in Crores)
Particulars Q1
FY20 : Q1 FY19 : %
Change
Formulation
USA 596
345 73%
EX-USA 175 108
62%
India 306 324
-6%
API 264 172 54%
Total 1341
949 41%
The Profit break-up is as
under: (Rs in Crores)
Particulars Q1
FY20 Q1 FY19 %
Change EBITDA 416 200 108%
EBITDA% 31% 21%
Profit Before Tax
368 160 131%
after Exceptional Items
Net Profit after Tax 301 124
144
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited,
a vertically integrated
research and development pharmaceutical company, has been at the forefront of healthcare since
1907.
Headquartered in India,
Alembic is a
publicly listed company
that manufactures and markets
generic pharmaceutical
products all over
the world.
Alembic's state
of the art research
and manufacturing facilities are approved by regulatory authorities of
many developed countries including the US FDA.
Alembic is one of the leaders in
branded generics in India.
Alembic's brands, marketed through a marketing team of over
5000 are well recognized by doctors and patients.
FINANCIAL HIGH LIGHTS (INR BNS)
Particulars Q1 FY21 Q1 FY20 Growth YTD FY20
Net Sales 13.41 9.49 41% 46.06
EBIDTAPre R&D 5.49
3.3 166% 18.15
Margin % 41% 35% 39%
R&D 1.41 1.39 2% 6.45
R&D % 11% 15% 14%
EBIDTA Post R&D 4.16 2.00 108% 12.13
Margin % 31% 21% 26%
Net Profit 3.01 1.24 144% 8.29
Capex 1.42 1.7 46.97
Debt‐Equity (Net) 0.33 0.35 0.52
Well‐established US front end
having strong customer base
Expanded
our capabilities to deliver a diverse portfolio to the US market
72
products launched through the US front end (3 launched in Q1FY21), 7 products
are on partner label
5
products planned to be launch in
Q2FY21
Ex‐US driven by partnership
Presence
in following markets‐
Europe, Canada, Australia, Brazil and South Africa
The
business will focus on new launches across key markets
Plant
successfully audited by key regulatory authorities across the globe
APIs
Sales
across geographies as preferred supplier
Investing
in plants to create additional capacities
FDA
Compliant plants
State
of the art R&D center and Process development lab
109
DMF filings on cumulative basis
R&D CAPABILITIES
Formulation:Vadodara,
Hyderabad and USA API:Vadodara and Hyderabad
Bio Centre :Vadodara
1200+ R&D employees
with diverse skill SETS
11 Filings &7
Approvals were contributed by acquisition of Orit,US in FY18
No comments:
Post a Comment